Showing results (41-50 of 105) with videos related to

Sort By:
Pageof 11
The Oncologist|February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinicFilip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
Plos One|August 11, 2011
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancersFilip Janku, J Jack Lee, Apostolia M Tsimberidou, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathiesRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Discovery Medicine|January 1, 2015
Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Molecular Cancer Therapeutics|June 16, 2011
A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancerManuel Hidalgo, Elizabeth Bruckheimer, N V Rajeshkumar, et al.
Discovery Medicine|March 1, 2015
Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndromeRishi Agarwal, Sarah Liebe, Michelle L Turski, et al.
Plos One|June 22, 2023
Feasibility and acceptability of an mHealth, home-based exercise intervention in colorectal cancer survivors: A pilot randomized controlled trialAnn Marie Moraitis, Nathan B Rose, Austin F Johnson, et al.
Clinical Colorectal Cancer|April 28, 2012
Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experienceDavid S Hong, Jesal C Patel, Jennifer Wheler, et al.
Plos One|June 8, 2012
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitorsIgnacio Garrido-Laguna, David S Hong, Filip Janku, et al.
Pageof 11